The TCGA ovarian cancer database shows that about 10% of patients respond poorly to platinum-based chemotherapy, with tumors relapsing in seven months or less.
I. INTRODUCTION

A. Background
Ovarian cancer is the fifth most deadly form of cancer for females, after lung, breast, colon and pancreatic cancers. It is estimated that in the United States during 2015, there will be 21,290 new cases of ovarian cancer, and 14,180 deaths [5] . Standard front-line therapy for ovarian cancer consists of some form of taxane (paclitaxel) coupled with some form of platinum (cisplatin or carboplatin), referred to hereafter as platinum-based chemotherapy. Patient response to front line therapy is not uniform. Since it is not possible to monitor a patient continually to assess response to therapy, one can use progression-free survival (PFS) or overall survival (OS) as somewhat imperfect proxies for patient response. Initially 70% to 80% of patients appear to respond to front line therapy [6] . However, based on the TCGA ovarian clinical data [1], about 10% of patients have PFS of seven months or less. At the opposite end of the spectrum, about 10% of patients enjoy PFS of three years or more. Among the rest, most ultimately relapse and die of disease progression [7] .
At the moment, there are more than a dozen molecular signatures that claim to predict the survival prospects of an ovarian cancer patient based on her genetic profile. Yet, according to [2] , none of these performs significantly better than pure guessing. The objective of the present paper is to develop yet another signature based on a recently developed algorithm called "lone star" [3] that is specifically intended for biological applications, and then validate it on an independent data set.
If there is a set of genetic biomarkers that are indicative of patient response, their influence is likely to be more pronounced at the two extreme ends of patient response. If we succeed in developing one or more classifiers that are capable of discriminating between these two extreme cases, then these classifiers can be extended to encompass nonextreme cases as well. That is precisely the approach adopted in the present paper.
B. Contributions of the Paper
In the present paper we analyze the TCGA ovarian cancer data, specifically gene expression levels as molecular measurements, and progression-free survival (PFS) as a clinical parameter. Biomarkers to discriminate between extremes with respect to this clinical parameter are extracted in a data-driven manner, using a new algorithm that has been developed specifically for biological applications [3] , called the "lone star" algorithm. The source code of a Matlab implementation of the lone star algorithm is freely available at the following URL:
http://sourceforge.net/projects/lonestar/ Therefore the algorithm can be readily used by even those unfamiliar with machine learning theory, without having to get into its inner workings. The biomarker panel developed on the TCGA data is then validated on an independent data set due to [4] .
II. APPROACH
The broad approach adopted in the paper is now described. The TCGA Agilent data set [1] is chosen as the training data set, while the TCGA Affymetrix data set [1] and the Tothill data set [4] are chosen for validating the predictions. The TCGA Affymetrix data set serves to establish that our method is portable across platforms, while the Tothill data set serves to establish that our method is portable both across platforms as well as data sets.
Given the training data set, the top 33 percentile in terms of patient response are defined to be super-responders (SR) and the bottom 33 percentile are defined to be non-responders (NR). Those in the middle are defined to be mediumresponders (MR). Then a recently proposed algorithm [3] , [8] , known as "lone star," is applied to the training data, after the initially large number of features (genes) are pruned by some pre-filtering. This step results in the definition of a discriminant function on the reduced feature set, which can be used to assign patients to the three bins: SR, MR and NR. Then the performance of the classifier is evaluated on the training as well as the test data sets. The evaluation is done in two ways, one of which is further subdivided: In evaluation 1(a), the AUROC is computed for just the SR and NR samples, for the training as well as the test data. In evaluation 1(b), the 3×3 contingency table of the actual versus predicted labels is determined, and the P -value (likelihood of obtaining the results the table by pure chance) is computed. In the second evaluation, the discriminant function is computed for all patients in the sample pool. The patients are then grouped into two classes, namely: those whose discriminant value is positive, and those with negative discriminant values. In principle, if our prediction methodology is any good, the positive class should have a survival advantage over the negative class. Kaplan-Meier curves are plotted for the two groups, and the P -value of the results obtained is computed for each case.
Within the framework of the above general approach, several variations are possible, as decribed below. All of these variations have been studied. However, in the interests of brevity, only one set of results is reported here.
• What percentile value should be chosen? Very small percentile values would cause almost all patients to be labelled as medium-responders, while overly large percentile values would cause almost no one to be classified as a medium-responder. Various percentile values ranging from 10 to 50 were tried. The best results were obtained with 33-percentiles, meaning that the top one-third, middle one-third, and bottom one-third, were labelled as SR, MR, and NR respectively. Therefore only those results are reported, though the results for other choices of X are available upon request.
• "Patient response" can be measured in two different ways, namely overall survival (OS), and progressionfree survival (PFS). Though these two are broadly correlated, the correlation is by no means perfect. For instance, overall survival is determined not just by the efficacy of the therapy, but by other factors such as age, general health, etc. Progression-free survival is also subjective, because the date on which a tumor is recorded as having progressed is the day on which it is observed to have progressed, whereas in reality the progression would have taken place at some date between that observed date, and the date of the previous check-up. Thus the disparity between the recorded date of progression and the actual date of recurrence could be several months. Therefore predictors were developed based on each parameter, and their performance was compared.
• While developing the classifier for the training data, it is not desirable to run the lone star algorithm using all 12,000+ genes. Some prefiltering is desirable, based on a combination of two attributes: (i) the t-test statistic that compares the mean value of a gene over the groups, and (ii) the fold change of the mean values over each group. The prefiltering can either be "loose," resulting in a large number of initial features which are then reduced further via the lone star algorithm, or else the prefiltering can be "tight," meaning that the initial feature set passed on to the lone star algorithm is rather small. The above discussion can be summarized as in Table I . All of these variations have been tried, but only the results for percentile value equal to 33%, clinical parameter as progression-free survival, and tight pre-filtering, are reported.
III. SELECTION CRITERIA
A. Survival Times
In the TCGA database, there are 565 samples for which information is available on days-to-death, days-to-recurrence and/or days-to-last-follow-up. We used overall survival (OS) progression-free survival (PFS) to defined eight different classes for training purposes and tested the whole patient sample in different cohorts. As stated above, various percentile values were tried, but choosing 33% gave the best results. With progression-free survival (PFS) used as the criterion, patients with PFS ≤ 283 days were classified as non-responders (NR), while patients with PFS ≥ 574 days were classified as super-responders (SR). these break points produced 189 NR, 188 MR and 188 SR. However, when the classifier was applied to the Tothill data set, the labels of NR, MR and SR were determined solely on the basis of the progression-free survival time. Consequently, the fraction of Fig. 1 . ROC for the classifier using overall survival (OS) with tight prefiltering the NR, MR and SR samples on the Tothill test data set did not necessarily correspond to the 33rd percentiles.
B. Pre-Filtering Criteria
For each of these situations, a binary classifier was trained, based on the corresponding SR and NR samples for the TCGA Agilent data set. The set of roughly 12,000 genes that are present on both the Agilent and Affymetrix platforms was taken as the master feature set. These genes were prefiltered using two criteria. The "tight" pre-filtering used the following parameters: Fold-change of at least = 1.25 between the averages of a gene's expression level over the two classes, and P -value of at most = 0.05 between the average expression levels of the two classes, as computed using the t-test. This resulted in the retention of just 59 genes out of roughly 12,000, whether PFS or OS was used. The "loose" pre-filtering used the following parameters: Foldchange of at least 1.175, and P -value at most 0.1. This resulted in 208 genes selected for the overall survival, and 181 genes selected for progression-free survival. Only the results for tight pre-filtering are reported here.
IV. TRAINING OF BINARY CLASSIFIERS
The gene expression levels of these pre-filtered genes were then converted to Z-scores, so as to facilitate their application across platforms. The lone star algorithm was run for eight (8) iterations using these features.
With tight filtering and 59 genes as the starting point, the algorithm resulted in 25 genes being chosen as the most predictive features for progression-free survival (PFS). Once the classifier is built, ROC curves were constructed by varying only the bias or threshold term to trade-off between sensitivity and specificity. The ROC curves and AUROC for this case are shown in Figures 1 and 2 respectively.
V. 3 × 3 CONTINGENCY TABLES
In the previous section we reported the outcome of applying the SR-NR classifier to the SR and NR samples Fig. 2 . ROC for the classifier using progression-free survival (PFS) with tight pre-filtering of the corresponding data sets, namely TCGA and Tothill. However, in order to be useful, any classifier must classify all samples, not just those already known to belong to one extreme or the other. In this section, all the samples of TCGA Agilent, TCGA Affymetrix, and Tothill, were assigned labels of NR, MR or SR as follows: The discriminant function values corresponding to all samples were computed, using the Z-scores of the gene expression values of the chosen 25 features (genes). Then the discriminant values were sorted. For the TCGA Agilent and TCGA Affymetrix data sets, the top 33% were assigned the label of SR, the bottom 33% were assigned the label of NR, and those in the middle were assigned the label of MR. These gave the predicted labels. The actual or true labels were determined by sorting the samples in terms of the overall survival, or progression-free survival, as the case may be, and then sorting the samples. Again, the top 33% were assigned the label of SR, the bottom 33% were assigned the label of NR, and those in the middle were assigned the label of MR. For the Tothill data set, first the number of SR, MR, and NR samples were determined using the cutoffs for OS or PFS, as appropriate. For OS, these numbers were 40, 98, and 28 SR, MR, NR. Therefore the patients with the 40 highest discriminant scores were labelled as SR, the bottom 28 scores as NR, and those in-between as MR. The exercise was repeated for PFS times, resulting in 40, 88, and 43 SR, MR, and NR.
For a 3 × 3 contingency table, the relevant quantity is the P -value of arriving at these labels purely through chance. When the total number of sample is greater than 50, which is the case in all of these data sets, it is possible to use the χ 2 -approximation to compute the P -values. The tables below show all of these values.
VI. KAPLAN-MEIER CURVES
Using the discriminant function based on the TCGA Agilent data, discriminant values were computed for all samples based on Z-scores for TCGA Agilent, TCGA Affymetrix, and Tothill data sets. Patients were divided into two groups: Those for whom the discriminant value is positive, and those for whom the discriminant value is negative. Kaplan-Meier curves were plotted to see whether the survival advantage between the two groups was statistically significant. The graphs below show the results. The conclusions are fairly unmistakeable. The classification using tight prefiltering gives far more statistically significant separation between the two classes, than that using loose prefiltering. However, if the classifiers based on progression-free survival are used, then both sets of classifiers give a statistically significant separation, whether survival advantage is measured using overall survival or progression-free survival.
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